ROE của cổ phiếu IRD là bao nhiêu?

OPUS GENETICS, INC. có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) 233.29%.

Tỷ suất cổ tức của IRD là bao nhiêu?

OPUS GENETICS, INC. có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của IRD là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của IRD ở mức 54/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu IRD không?

Điểm AI Timing của IRD là 50/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu IRD thuộc ngành nào?

OPUS GENETICS, INC. được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu IRD (NASDAQ) | OPUS GENETICS, INC.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

IRD AI Analysis Summary

Our AI summary for IRD: OPUS GENETICS, INC. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 233.29%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

IRD

OPUS GENETICS, INC.

US:NASDAQ STOCK Healthcare >> Biotechnology News 95

USD 3.71

-0.13 (-3.39%) Day Change

Watchlist Portfolio Compare Chart

-0.03

D/E

233.3%

ROE

-160.1%

ROA

0.00%

Div Yield

OPUS GENETICS, INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.71 Price -0.13 (-3.39%) Day Change	NEWS SCORE: 95

IRD Chất lượng tổng thể của cố phiếu Không tốt lắm ( Chất lượng = 54) và Thời điểm mua ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	95
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.71
PBV / Sector	-6.92 / 5.20
Earning Per Share	-1.25

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	3.06 M GREAT
Average 1W Daily Value	2.94 M GREAT

Yếu tố Kỹ thuật

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-892.36 / 98.71
NPM Average (%) / Sector	-354.53 / -1,721.76
NPM Change Average (%) / Sector	200.96 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-160.11 / 27.02
ROA Average (%) / Sector	-79.38 / -368.17
ROA Change Average (%) / Sector	154.48 / 5,404.12 GREAT
ROE (%) / Sector	233.29 / 3.47 GREAT
ROE Average (%) / Sector	-185.35 / 6.51
ROE Change Average (%) / Sector	947.47 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Chi tiết đăng ký

Analyze Date	2026-08-01 08:00:02
Symbol	IRD
Name	OPUS GENETICS, INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	82.57 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	317.05 / 9,903.94

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 8 Davis Drive, Durham, NC, United States, 27713

Phone: 984 884 6030

Website: https://opusgtx.com

Sector: Healthcare >> Biotechnology

Description: Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.